Literature DB >> 29208318

Liver resection is justified for patients with bilateral multiple colorectal liver metastases: A propensity-score-matched analysis.

Kiyohiko Omichi1, Junichi Shindoh2, Jordan M Cloyd1, Takashi Mizuno1, Yun Shin Chun1, Claudius Conrad1, Thomas A Aloia1, Ching-Wei D Tzeng1, Jean-Nicolas Vauthey3.   

Abstract

BACKGROUND: Increasingly, patients with multiple colorectal liver metastases (CLM) are surgically treated. Some studies have shown that patients with bilobar and unilobar multiple CLM have similar outcomes, but other have shown that patients with bilobar CLM have worse outcomes after resection. We aimed to compare clinical outcomes of surgical treatment of bilobar and unilobar CLM using propensity score matching.
METHODS: The single-institution study included patients who underwent hepatectomy for ≥3 histologically confirmed CLM during 1998-2014. Clinicopathologic characteristics and long-term outcomes were compared between patients with bilobar and unilobar CLM in a propensity-score-adjusted cohort.
RESULTS: A total of 473 patients met the inclusion criteria, 271 (57%) with bilobar and 202 (43%) with unilobar CLM. In the propensity-score-matched population (bilobar, 170; unilobar, 170), no differences were observed according to the distribution of CLM except for a greater frequency of concomitant ablation, and R1 resection in the bilobar group. There was no difference between the bilobar and unilobar groups in 5-year overall survival rates (46% and 49%, respectively; P = 0.740) or 3-year recurrence-free survival rates (21% and 24%, respectively; P = 0.674).
CONCLUSIONS: Tumor distribution may not affect the curability of surgery for multiple CLM. Liver resection would be justified for selected patients with bilobar CLM.
Copyright © 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Bilobar; Colorectal liver metastases; Liver resection; Overall survival; Recurrence-free survival

Mesh:

Year:  2017        PMID: 29208318      PMCID: PMC5742306          DOI: 10.1016/j.ejso.2017.11.006

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  36 in total

1.  Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.

Authors:  Scott Kopetz; George J Chang; Michael J Overman; Cathy Eng; Daniel J Sargent; David W Larson; Axel Grothey; Jean-Nicolas Vauthey; David M Nagorney; Robert R McWilliams
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

2.  Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome.

Authors:  B Cady; R L Jenkins; G D Steele; W D Lewis; M D Stone; W V McDermott; J M Jessup; A Bothe; P Lalor; E J Lovett; P Lavin; D C Linehan
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

3.  Propensity scores as a basis for equating groups: basic principles and application in clinical treatment outcome research.

Authors:  Stephen G West; Heining Cham; Felix Thoemmes; Babette Renneberg; Julian Schulze; Matthias Weiler
Journal:  J Consult Clin Psychol       Date:  2014-04-07

4.  Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients.

Authors:  Myrddin Rees; Paris P Tekkis; Fenella K S Welsh; Thomas O'Rourke; Timothy G John
Journal:  Ann Surg       Date:  2008-01       Impact factor: 12.969

5.  Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate?

Authors:  Eran Sadot; Bas Groot Koerkamp; Julie N Leal; Jinru Shia; Mithat Gonen; Peter J Allen; Ronald P DeMatteo; T Peter Kingham; Nancy Kemeny; Leslie H Blumgart; William R Jarnagin; Michael I DʼAngelica
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

6.  Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry.

Authors:  Yoji Kishi; Eddie K Abdalla; Yun Shin Chun; Daria Zorzi; David C Madoff; Michael J Wallace; Steven A Curley; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2009-10       Impact factor: 12.969

Review 7.  Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus.

Authors:  René Adam; Aimery de Gramont; Joan Figueras; Norihiro Kokudo; Francis Kunstlinger; Evelyne Loyer; Graeme Poston; Philippe Rougier; Laura Rubbia-Brandt; Alberto Sobrero; Catherine Teh; Sabine Tejpar; Eric Van Cutsem; Jean-Nicolas Vauthey; Lars Påhlman
Journal:  Cancer Treat Rev       Date:  2015-06-30       Impact factor: 12.111

8.  Patient selection for hepatic resection of colorectal metastases.

Authors:  H J Wanebo; Q D Chu; M P Vezeridis; C Soderberg
Journal:  Arch Surg       Date:  1996-03

9.  Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival.

Authors:  Yun Shin Chun; Jean-Nicolas Vauthey; Dario Ribero; Matteo Donadon; John T Mullen; Cathy Eng; David C Madoff; David Z Chang; Linus Ho; Scott Kopetz; Steven H Wei; Steven A Curley; Eddie K Abdalla
Journal:  J Gastrointest Surg       Date:  2007-09-11       Impact factor: 3.452

10.  Determinants of long-term outcome in patients undergoing simultaneous resection of synchronous colorectal liver metastases.

Authors:  Qi Lin; Qinghai Ye; Dexiang Zhu; Ye Wei; Li Ren; Lechi Ye; Qingyang Feng; Pingping Xu; Peng Zheng; Minzhi Lv; Jia Fan; Jianmin Xu
Journal:  PLoS One       Date:  2014-08-27       Impact factor: 3.240

View more
  5 in total

1.  Possibility of repeat surgery for recurrence following two-stage hepatectomy for colorectal liver metastases: impact on patient outcome.

Authors:  Francesco Ardito
Journal:  Hepatobiliary Surg Nutr       Date:  2020-02       Impact factor: 7.293

2.  Hepatectomy with Perioperative Chemotherapy for Multiple Colorectal Liver Metastases is the Available Option for Prolonged Survival.

Authors:  Kiyohiko Omichi; Yosuke Inoue; Yoshihiro Mise; Atsushi Oba; Yoshihiro Ono; Takafumi Sato; Hiromichi Ito; Yu Takahashi; Akio Saiura
Journal:  Ann Surg Oncol       Date:  2022-02-03       Impact factor: 5.344

3.  Development of a patient-reported outcome tool for assessing symptom burden during perioperative care in liver surgery: The MDASI-PeriOp-Hep.

Authors:  Xin Shelley Wang; Qiuling Shi; Loretta A Williams; Heather A Lillemoe; Ting-Yu Chen; Vijaya Gottumukkala; Araceli Garcia-Gonzalez; Donna Malveaux; Mona Kamal; Charles S Cleeland; Thomas A Aloia
Journal:  Eur J Oncol Nurs       Date:  2021-04-28       Impact factor: 2.588

Review 4.  Current status of surgical treatment of colorectal liver metastases.

Authors:  Feng Xu; Bin Tang; Tian-Qiang Jin; Chao-Liu Dai
Journal:  World J Clin Cases       Date:  2018-11-26       Impact factor: 1.337

5.  Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity score-matched survival analysis.

Authors:  Yang Gao; Peng-Xiang Wang; Jian-Wen Cheng; Yun-Fan Sun; Bo Hu; Wei Guo; Kai-Qian Zhou; Yue Yin; Yuan-Cheng Li; Jian Wang; Jun-Feng Huang; Shuang-Jian Qiu; Jian Zhou; Jia Fan; Xin-Rong Yang
Journal:  Cancer Med       Date:  2019-09-30       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.